Relmada Therapeutics (RLMD) – Press Releases
-
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
-
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
-
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
-
Relmada Therapeutics Provides Corporate Update
-
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
-
Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023
-
Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023
-
Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
-
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress
-
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder
-
Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder
-
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
-
Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
-
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
-
Relmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023
-
Bragar Eagel & Squire, P.C. Is Investigating Relmada, Arrival, FMC, and Viasat and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Relmada, DoubleVerify, and Castle and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Chegg, and Relmada and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Chegg, and Relmada and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Is Investigating Seagate, Chegg, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Is Investigating Relmada, DoubleVerify, Sanmina, and JinkoSolar and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Seagate, Chegg, and Relmada and Encourages Investors to Contact the Firm
-
RLMD INVESTOR NEWS: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – RLMD
-
Relmada Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
-
Bragar Eagel & Squire, P.C. Is Investigating Relmada, Bowlero, and Integra and Encourages Investors to Contact the Firm
-
Relmada Therapeutics to Participate in the 2023 Jefferies Global Healthcare Conference
-
Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2023 Annual Meeting
-
Bragar Eagel & Squire, P.C. Is Investigating Relmada, and Sanmina and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Is Investigating Fox, Cutera, and Relmada and Encourages Investors to Contact the Firm
-
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
-
Relmada Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11, 2023
-
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
-
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 23, 2023
-
Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors
-
Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer
-
Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder
-
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
-
Relmada Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 10, 2022
-
Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder
-
Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder
-
Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
-
Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder
-
Relmada Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022
-
Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial
-
Anthos Therapeutics to Host Discussion with Global Experts on the Promise of Factor XI Inhibition at the 2022 BIO International Convention
-
Relmada Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
-
Relmada Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference
-
Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2022 Annual Meeting
-
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
Back to RLMD Stock Lookup
